Gene editing therapeutics based on mRNA delivery.


Journal

Advanced drug delivery reviews
ISSN: 1872-8294
Titre abrégé: Adv Drug Deliv Rev
Pays: Netherlands
ID NLM: 8710523

Informations de publication

Date de publication:
09 2023
Historique:
received: 30 04 2023
revised: 20 07 2023
accepted: 26 07 2023
medline: 28 8 2023
pubmed: 30 7 2023
entrez: 29 7 2023
Statut: ppublish

Résumé

The field of gene editing has received much attention in recent years due to its immense therapeutic potential. In particular, gene editing therapeutics, such as the CRISPR-Cas systems, base editors, and other emerging gene editors, offer the opportunity to address previously untreatable disorders. This review aims to summarize the therapeutic applications of gene editing based on mRNA delivery. We introduce gene editing therapeutics using mRNA and focus on engineering and improvement of gene editing technology. We subsequently examine ex vivo and in vivo gene editing techniques and conclude with an exploration of the next generation of CRISPR and base editing systems.

Identifiants

pubmed: 37516409
pii: S0169-409X(23)00341-1
doi: 10.1016/j.addr.2023.115026
pii:
doi:

Substances chimiques

RNA, Messenger 0

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

115026

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH125979
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI164559
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB029320
Pays : United States
Organisme : NIDA NIH HHS
ID : R61 DA048444
Pays : United States
Organisme : NINDS NIH HHS
ID : UG3 NS115599
Pays : United States

Informations de copyright

Copyright © 2023. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Juliana Popovitz (J)

GenEdit, 681 Gateway Blvd., South San Francisco, CA 94080, USA.

Rohit Sharma (R)

Department of Bioengineering, University of California, Berkeley, CA 94720, USA; Innovative Genomics Institute, 2151 Berkeley Way, Berkeley, CA 94704, USA.

Reyhane Hoshyar (R)

GenEdit, 681 Gateway Blvd., South San Francisco, CA 94080, USA.

Beob Soo Kim (B)

GenEdit, 681 Gateway Blvd., South San Francisco, CA 94080, USA.

Niren Murthy (N)

Department of Bioengineering, University of California, Berkeley, CA 94720, USA; Innovative Genomics Institute, 2151 Berkeley Way, Berkeley, CA 94704, USA. Electronic address: nmurthy@berkeley.edu.

Kunwoo Lee (K)

GenEdit, 681 Gateway Blvd., South San Francisco, CA 94080, USA. Electronic address: lee@genedit.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH